![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis PR Newswire WALTHAM, Mass., July 9, 2024 -- Exceeded enrollment target due...
Q32 Bio Joins Russell 3000® Index PR Newswire WALTHAM, Mass., July 1, 2024 WALTHAM, Mass., July 1, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 3.76 | 14.3675964845 | 26.17 | 29.99 | 24.7 | 64567 | 27.54238308 | CS |
4 | 14.38 | 92.4758842444 | 15.55 | 29.99 | 13.59 | 85776 | 21.54085701 | CS |
12 | 1.6 | 5.64772326156 | 28.33 | 32.88 | 13.59 | 58389 | 22.97890019 | CS |
26 | 13.69 | 84.2980295567 | 16.24 | 32.88 | 13.59 | 55610 | 23.3654574 | CS |
52 | 13.69 | 84.2980295567 | 16.24 | 32.88 | 13.59 | 55610 | 23.3654574 | CS |
156 | 13.69 | 84.2980295567 | 16.24 | 32.88 | 13.59 | 55610 | 23.3654574 | CS |
260 | 13.69 | 84.2980295567 | 16.24 | 32.88 | 13.59 | 55610 | 23.3654574 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions